Xueba’s medical black technology system

Chapter 182 Lu Liang’s Report

After chatting for a while, the foreign scholar turned around and left with a still unsatisfied look on his face, and Lu Liang also let out a long sigh of relief.

Just when Lu Liang was about to sit down, he realized that many people in the venue were looking at him.

Many of these looks were curious, but most of them were surprised.

He seemed to be surprised by Lu Liang's youth.

Some of them were even eager to come forward and talk.

However, the meeting was about to start soon, which made other people have no choice but to give up these thoughts for the time being.

As the time approached eight o'clock, everyone present found their seats and sat down one after another.

Soon, the meeting began.

The organizer of this meeting, the president of the International Lung Cancer Association, took the stage to speak. The content of his speech was probably some polite thanks, without much substantive content.

After the opening remarks, the entire meeting entered the formal stage. The chairman first introduced some of the procedures of the entire meeting and briefly introduced the three academic lecture halls.

For participants at the venue, they can freely enter and exit any of the three lecture halls and choose the reports they are interested in.

But Lu Liang couldn't. At least he couldn't leave the lecture hall until he completed his report.

After all, if it was his turn to report, he would be in trouble if he couldn't find anyone.

Like Lu Liang, there are review experts sitting in the front row. Each lecture hall invites some big names in the field to serve as review experts to review the papers reported at the conference.

Soon, the first scholar to report came on stage. As the giant LED screen in the lecture hall lit up, the content of the report soon appeared on the screen.

This scholar reported on research on drug resistance in lung cancer.

Lung cancer cells are resistant to the third-generation targeted drug osimertinib, which is a dilemma that many lung cancer patients currently face when receiving targeted therapy.

Based on this problem, the scholar broke through the bottleneck of resistance of lung cancer cells to osimertinib alone through a new drug combination of osimertinib and servotinib.

In this study, through combination therapy, the ORR of drug-resistant patients with high MET expression reached 49%, which means that half of the patients who received this treatment had their lesions shrunk by more than 30%.

The scholar carefully described his research through data charts displayed on a large screen.

Lu Liang was listening carefully in the audience. The content that could be reported at such a conference was without exception extremely valuable research.

Soon, the first scholar's report was over. Lu Liang glanced at the time. It was exactly 19 and a half minutes.

Each person had only 10 minutes to report. It can be said that this scholar just squeezed the time.

It seems that the other party has practiced it countless times before taking the stage, otherwise he would not be able to grasp the time so accurately.

As the first scholar finished speaking, the audience burst into warm applause.

Some of the scholars present are doctors and professors from major cancer hospitals. The research of the first scholar is undoubtedly of great value to them.

In the future, they will have a new treatment method for lung cancer patients who have become resistant to osimertinib.

Soon, it was the turn of the second scholar to report.

It's a pity that the second scholar didn't have many outstanding performances.

The reason is also very simple. The second scholar's report exceeded the time limit, and the research content was not as exciting as the first scholar's report.

This caused many scholars in the audience to look impatient on their faces during his report.

Therefore, after the second scholar finished his report, the applause from the audience was not as enthusiastic as the first one, and everyone just clapped politely.After all, in a conference of this level, everyone will subconsciously believe that low-level mistakes such as timeouts should not happen, even if it is just a few minutes.

He didn't interrupt the report or discuss other things in whispers, which was already considered a great honor.

The scholar seemed to be aware of the mistake he had made, and could only squeeze out a slightly embarrassed smile on his face.

The reports of the first two scholars lasted about 10 minutes, plus some questions and exchanges after the report. By the end of the report, the time had come to 09:30.

Lu Liang stood up, because it was his turn to make a report next.

However, when Lu Liang actually stood on the stage, the scene he saw made him click his tongue.

At this moment, the audience can be said to be full of people. Even when there are no seats available, some people simply stand in the aisle or at the back to listen.

There were even a steady stream of people coming from other lecture halls, all of whom came for Lu Liang's report.

After Lu Liang took the stage, there was a small discussion in the audience.

"Wardfa, are the organizers not mistaken? Is this really Lu Liang, the developer of PD-1/TIGIT inhibitors?"

"Isn't this a little too young?"

"Don't judge others based on their appearance. Remember that the person who discovered magic-angle graphene in the field of physics was also a young man."

"But then again, that young man seems to be a scholar from China. In the past two years... tsk tsk tsk."

Lu Liang didn't pay attention to the comments in the audience. He was currently concerned about another matter.

Lu Liang suddenly understood why the second scholar made mistakes in his report.

Faced with so many experts in the professional field, any detail error in the presenter's research will be spotted by the scholars in the audience, and then discussed and questioned.

In this case, the pressure on the person to report on the stage is undoubtedly huge.

And Lu Liang had to bear more pressure than that, because he saw Brennan sitting under the stage. At this moment, Brennan had slowly sat upright, and he grinned at Lu Liang.

His eyes seemed to be looking at a prey waiting to be slaughtered.

In addition, there were reporters in the aisles on both sides with cameras, and the lenses were also pointed at Lu Liang on the stage, including some reporters from China.

"If Brennan finds problems with this report, it will probably be widely reported by reporters."

Thinking of this, Lu Liang suddenly felt the pressure doubled.

However, Lu Liang also saw Ji Hong sitting in the audience.

Ji Hong smiled slightly and gave Lu Liang a thumbs up, indicating that Lu Liang could speak boldly without worrying about other things.

Lu Liang breathed a long sigh of relief and calmed down his mood a little. Then he nodded to the staff in the audience, and then the ppt he prepared appeared on the big screen.

At this moment, Lu Liang also slowly spoke: "As we all know, as the research on cellular immunotherapy continues to deepen, there are countless studies on the application of cellular immunotherapy in non-small cell lung cancer."

"Today, as lung cancer patients are gradually developing resistance to targeted drugs, cellular immunotherapy has become one of the important methods for treating non-small cell lung cancer."

"It is well known that human natural killer NK cells also express PD-1 and have the potential to prolong the survival of patients with advanced non-small cell lung cancer. So, I was wondering whether combining PD-1 antibody drugs and NK would have any effect. To the effect of 1+1>2.”

“Based on this idea, I have today’s report!”

(End of this chapter)